Objective-Elastin is the major structural extracellular matrix component of the arterial wall that provides the elastic recoil properties and resilience essential for proper vascular function. Elastin-derived peptides (EDP) originating from elastin fragmentation during vascular remodeling have been shown to play an important role in cell physiology and development of cardiovascular diseases. However, their involvement in thrombosis has been unexplored to date. In this study, we investigated the effects of EDP on (1) platelet aggregation and related signaling and (2) thrombus formation. We also characterized the mechanism by which EDP regulate thrombosis. Approach and Results-We show that EDP, derived from organo-alkaline hydrolysate of bovine insoluble elastin (kappaelastin), decrease human platelet aggregation in whole blood induced by weak and strong agonists, such as ADP, epinephrine, arachidonic acid, collagen, TRAP, and U46619. In a mouse whole blood perfusion assay over a collagen matrix, kappa-elastin and VGVAPG, the canonical peptide recognizing the elastin receptor complex, significantly decrease thrombus formation under arterial shear conditions. We confirmed these results in vivo by demonstrating that both kappa-elastin and VGVAPG significantly prolonged the time for complete arteriole occlusion in a mouse model of thrombosis and increased tail bleeding times. Finally, we demonstrate that the regulatory role of EDP on thrombosis relies on platelets that express a functional elastin receptor complex and on the ability of EDP to disrupt plasma von Willebrand factor interaction with collagen.
V ascular remodeling underlies the pathogenesis of major cardiovascular diseases and involves degradation and reorganization of the extracellular matrix of the vessel wall. Elastin is the major component of elastic fibers and represents one of the main structural matrix components of the vascular wall together with collagens. This highly stable molecule with longevity comparable to human lifespan 1-3 is essential for maintaining the strength, resilience, and integrity of the vessel wall. [4] [5] [6] Local inflammation concurrently with increased elastase activity, calcium, and lipid deposits are typical features of physiological and pathological vascular aging that contribute to elastin degradation. [7] [8] [9] [10] [11] Elastin degradation releases bioactive elastin-derived peptides (EDP) known as elastokines. Among them, peptides harboring the GxxPG motif, such as the canonical VGVAPG peptide, have been shown to act on several cells, such as endothelial cells, monocytes, and smooth muscle cells. 8 Most of their effects have been assigned to their interaction with the elastin receptor complex (ERC). The ERC is a singular membrane receptor composed of 3 subunits: a peripheral 67-kDa subunit called elastin-binding protein (EBP), a 55-kDa protective protein/cathepsin A (PPCA), and a 61-kDa neuraminidase (Neuraminidase-1, Neu-1). 12 Considered for a long time as a mechanical support for cells, the extracellular matrix and its degradation products are now regarded as important regulators of cell physiology and development of vascular diseases. Accumulating evidence in the literature suggest that EDP may play important roles in the progression of age-related vascular diseases. For instance, a proatherogenic role of EDP has been recently described in ApoE −/− and LDLR −/− mice. 13 In addition, chronic accumulation of EDP has been shown to promote hyperglycemia and insulin resistance in mice. 14 Vascular aging is also associated with hemostasis dysregulation and increased thrombosis tendency. 15 However, the effect of EDP on thrombosis has never been studied to date.
In this study, we investigated the role of EDP in platelet aggregation and thrombus formation in vitro and in vivo using both human and mouse whole blood. We show for the first time that EDP regulate thrombosis by an original mechanism involving effects both at the platelet level and at the matrix level by competing for von Willebrand factor (vWF) immobilization on collagen. At the platelet level, we further demonstrate the existence of a functional ERC that is able to decrease washed platelet aggregation and to regulate thrombus formation in vitro and in vivo.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

EDP Decrease Human Platelet Aggregation and αIIbβ3 Activation in Whole Blood
The effects of EDP on platelet aggregation were first investigated in whole blood by impedance aggregometry with the Multiplate ® analyzer. As shown in Figure 1 , kappa-elastin (kE) significantly decreased platelet aggregation induced by weak (ADP, epinephrine, arachidonic acid) and strong (collagen, TRAP, U46619) platelet agonists. At 100 μg/mL kE, whole blood platelet aggregations were inhibited by ≈20%, 48%, and 36% for ADP, epinephrine, and arachidonic acid, respectively, and by 35%, 25%, and 45% for collagen, TRAP, and U46619, respectively ( Figure 1A and 1B).
We next evaluated the effects of kE on αIIbβ3 activation and CD62P surface exposure by flow cytometry. At resting state, kE had no effect on the activation level of αIIbβ3, P-selectin (CD62P), and phosphatidylserine surface expression ( Figure I in the online-only Data Supplement) and did not trigger tyrosine phosphorylation of platelet proteins ( Figure II in the online-only Data Supplement). In collagen-, TRAP-, and ADP-activated platelets, 100 μg/mL kE significantly decreased αIIbβ3 activation by 41.3%±8.8%, 46.3%±5.7%, and 37.1%±6.9%, respectively ( Figure 1C ). In contrast, no effect was observed on platelet granule secretion induced by collagen, TRAP, and ADP, as evidenced by anti-CD62P binding levels ( Figure 1D ).
Taken together, these data indicate that EDP affect platelet function in whole blood by decreasing both platelet aggregation and activation of αIIbβ3 without modifying platelet secretion. Importantly, when used alone, kE has no effect on platelet viability and activation.
EDP and VGVAPG Reduce Thrombus Formation In vitro Under Flow Conditions
The effects of EDP on platelet interaction with collagen under flow conditions were assessed using a whole blood perfusion assay over a fibrillar collagen matrix at 1500/s. As shown in Figure 2B , preincubation of mouse whole blood with 100 μg/mL kE significantly decreased the area covered by platelets from 60 seconds of perfusion. At 150 seconds, the inhibition reached 43% in the presence of kE (12.9%±2.2%) compared with control (22.8%±2.1%). To examine whether the ERC can reduce thrombus formation in vitro, we used the canonical VGVAPG peptide. This peptide was used at a 4-fold higher concentration than kE (400 μg/mL) because it has been demonstrated that a 4-fold higher concentration is necessary to achieve the equivalent physiological stimulation levels of bioactive elastin peptides released after elastin degradation. 13, 14, 16 As negative control, a scrambled VVGPGA peptide was used. 17, 18 As shown in Figure 2A and 2C, VGVAPG significantly decreased the area covered by platelets from 30 seconds of perfusion. At 150 seconds of perfusion, VGVAPG decreased by 30% the area covered by platelets compared with scrambled peptide (27.0%±3.7% versus 38.7%±4.5%).
All these data demonstrate that EDP and VGVAPG reduce thrombus formation in vitro and suggest the likely contribution of the ERC in this process.
EDP Disrupt Plasma vWF Immobilization Onto Collagen
Platelet interaction with collagen under flow conditions requires the initial rolling and slowing down of platelets through vWF immobilized onto collagen. We therefore investigated if part of the inhibitory effects observed in Figure 2 could be explained by disruption of vWF immobilization onto collagen. Increasing concentrations of kE (25-200 μg/mL) significantly decreased mouse and human plasma vWF binding to immobilized collagen ( Figure 3A and 3B). The maximal effect was observed at 100 μg/mL kE with 77.9%±7.1% and 87.0%±5.0% inhibition for mouse and human, respectively. Although statistically significant, VGVAPG decreased slightly mouse plasma vWF binding to immobilized collagen compared with kE. At 400 μg/mL, the inhibition was of 12.7%±2.3% ( Figure 3C ). No effect was observed for human plasma ( Figure 3D ). We next evaluated whether EDP could directly interact with vWF or collagen. Although both human and mouse plasma vWF did not interact with immobilized kE ( Figure 3E ), soluble kE dose-dependently interacted with immobilized collagen ( Figure 3F ).
Taken together, these data indicate that EDP, but not VGVAPG, are able to disrupt plasma vWF immobilization onto collagen by interacting with collagen and thereby competing for vWF binding.
VGVAPG Directly Affects Human Platelet Aggregation and Related Signaling
As the inhibitory effects of the VGVAPG peptide suggested the contribution of the ERC in platelets, we evaluated whether this peptide could inhibit collagen-induced washed platelet aggregation and related signaling. As shown in Figure 4A , washed platelet aggregation induced by 1 μg/mL collagen was significantly decreased by VGVAPG (63.9%±12.0%) compared with scrambled peptide (100.9%±5.4%). Comparable inhibition was reached at 100 μg/mL kE ( Figure 4A ). Platelet protein migrated at ≈65 kDa ( Figure 4B and 4C). Its phosphorylation level was significantly decreased by kE and VGVAPG compared with their respective control ( Figure 4C ).
Taken together, these results indicate that a functional ERC is present on platelets and is able to directly modulate platelet aggregation and related signaling.
EBP, Neu-1, and PPCA Are Expressed in Platelets and Form a Functional ERC
The Neu-1 subunit has been shown to play a critical role in ERC-mediated effects. 19 On binding of EDP to the EBP subunit, Neu-1 catalyzes the local conversion of GM 3 ganglioside into lactosylceramide as a result of its sialidase activity. 19 We checked for the presence of Neu-1 and PPCA in both human and mouse platelets by western blotting. Both ERC subunits were detected in human and mouse platelet lysates ( Figure 5A and 5B) . Overall, the migration patterns were similar between the 2 species with the exception of PPCA, suggesting differences in posttranslational modifications. Because of the unavailability of selective antibodies to detect EBP, we were unable to demonstrate the presence of EBP at the protein level. We therefore checked at the mRNA level in human megakaryocytes and normalized the expression to GAPDH. As shown in Figure 5D , EBP, Neu-1, and PPCA transcripts were unambiguously expressed in 2 different human megakaryoblastic cell lines (CHRF-288-11 and MEG-01) and in human CD34 + hematopoietic stem cells at 6 and 11 days after in vitro differentiation. 20 Similar results were observed when normalizing to another housekeeping gene, RPL32 ( Figure 5E ). To confirm the functionality of the receptor in human platelets, nonpermeabilized washed platelets were incubated with 100 μg/mL kE, and sialidase activity was assessed using the 2-O-(p-nitrophenyl)-α-d-Nacetylneuraminic acid as substrate. After 2 hours of incubation, kE significantly increased by 50.4%±3.0% sialidase activity in platelets ( Figure 5C ).
Together, these results demonstrate that EBP, Neu-1, and PPCA are well expressed in platelets and form a functional receptor able to trigger activation of its Neu-1 subunit.
EDP and VGVAPG Delay Thrombosis In Vivo
The effects of kE were finally investigated in in vivo thrombosis using the FeCl 3 -induced mesenteric arteriole thrombosis model. Ten minutes before the induction of thrombosis by 10% FeCl 3 , mice were intravenously injected with 10 mg/ kg kE or vehicle. 14 The time for the formation of a stable occlusive thrombus was significantly prolonged in kE-treated mice compared with vehicle-injected control mice (37.4±5.1 minutes versus 22.8±2.8 minutes, respectively; P=0.022; Figure 6A and 6B). To examine whether binding of VGVAPG to the ERC also delays thrombosis in vivo, mice were injected with VGVAPG (40 mg/kg) and compared with scrambled VVGPGA. As shown in Figure 6C , injection of VVGPGA increased by ≈2-fold the time to complete occlusion compared with saline-injected mice ( Figure 6B ), suggesting that this scrambled peptide had some unexpected effects in this model as in the in vitro model of thrombus formation wherein the scrambled peptide increased the area covered by platelets compared with saline ( Figure 2B and 2C) . However, when compared with VGVAPG-treated mice, occlusion times were significantly longer in these mice (75.3±2.7 minutes versus 50.5±4.7 minutes, respectively; P=0.001; Figure 6C ), suggesting that binding of VGVAPG to the ERC can regulate in vivo thrombosis. Together, these observations strongly indicate that circulating EDP affects thrombus formation in vivo and that the ERC is an important regulator in this process. The effects of EDP and VGVAPG were then evaluated in a tail-bleeding assay and bleeding times for kE-(707±17 seconds) and VGVAPG-(593±52 seconds) treated mice were significantly longer than those for saline-(360±40 s) and VVGPGA-(413±51 s) treated mice ( Figure 6D ). However, 33% of VVGPGA-treated mice showed no cessation of bleeding in the observed time period in contrast to 11% for VGVAPG-treated mice. Therefore, additional experiments are required to definitively prove that the ERC is involved in the regulation of tail bleeding time.
Discussion
EDP originating from elastin fragmentation are one of the major products of extracellular matrix degradation released during vascular aging. Generation of EDP is a typical feature of inflamm-aging 8 and correlates with occurrence of vascular stiffness, calcification, and lipid deposits. [9] [10] [11] 21, 22 A growing body of evidences now suggests that these extracellular matrix degradation products can also affect adjacent/circulating cells and contribute to the progression of age-associated vascular diseases. 21, 23 In this context, we recently demonstrated that chronic injection of EDP in mice potentiates atherosclerosis development and promotes insulin resistance, 14,24 2 events that mainly occur during aging. Human blood concentrations of EDP reported in the literature fluctuate tremendously according to the method used for EDP assay. [25] [26] [27] [28] However, blood EDP production has been shown to increase with the progression of various vascular diseases, such as in atherosclerosis, aneurysms, and chronic kidney disease. 22, 26, 28 For instance, serum EDP concentration in patients with chronic kidney disease at stages 3 and 4 has been measured at 57 μg/mL ranging from 43 to 78 μg/mL. 22 In wild-type C57Bl/6J male mice, blood EDP concentration was estimated at 7.7±1.1 mg/kg culminating at 14.2±1.1 mg/kg in high fat diet mice and 15.2±1.2 mg/kg in diabetic (db/db) mice. 14 Importantly, local concentrations of EDP at the site of injury are predicted to be even higher. Indeed, a specific feature of locally produced EDP is to increase further the elastolytic activity by acting on infiltrating cells at the site of vascular injury. This higher elastolytic activity will further increase elastin degradation and release of large amounts of EDP. This phenomenon is referred to as a self-propelled vicious circle, which could contribute to the progression and chronicity of vascular disease. 21 In this study, we investigated the effects of EDP in thrombosis, another age-related vascular disease. We took advantage of kE, widely used for a long time for research and industrial purposes. kE is a complex mixture of EDP that contains bioactive peptides harboring the GxxPG motif recognized by the ERC. By combining both in vitro and in vivo approaches, we demonstrated that circulating EDP regulate thrombosis and hemostasis by an original mechanism involving effects both at the platelet and at the matrix levels. At the platelet level, EDP were shown to significantly decrease human platelet aggregation in whole blood induced by several agonists, such as collagen, TRAP, U46619, ADP, epinephrine, and arachidonic acid, with a maximal inhibition culminating at 20% to 48% according to the agonist used. This inhibitory effect was associated with decreased αIIbβ3 activation, suggesting that binding of EDP to platelets may affect the inside-out signaling pathways leading to αIIbβ3 activation. No effect was, however, observed on α-granule secretion as evidenced by measuring CD62P binding to platelets in whole blood on agonist challenge. Because of the complex nature of kE, we systematically used the VGVAPG peptide versus a scrambled peptide (VVGPGA) in the following experiments to specifically focus on the ERC in these processes because this peptide is known to bind specifically to the EBP subunit of this receptor. 29, 30 Indeed, ≈29 different peptides were identified in kE mixtures by mass spectrometry analysis with one third containing the bioactive GxxPG motif (not shown). 14 In contrast, the scrambled VVGPGA is unable to adopt the type VIII β-turn conformation because of the lack of GxxPG motif. 30 However, previous studies have reported that simple proline-containing peptides, such as PG, WP, and PGP (putative fragments of collagen and elastin), possess significant antithrombotic and anticoagulant effects in vitro and in vivo. 31 This probably explains that the scrambled peptide used in the current study had some effects on platelets ( Figure 4C ) and on in vitro ( Figure 2C ) and in vivo ( Figure 6 ) experiments. Other scrambled peptides (GGVVAP, VGVGAP, GAGVVP, AVPVGG) were tested and showed similar effects (data not shown).
Using washed platelets, we next demonstrated that kE and the ERC directly affect platelet function by decreasing collagen-induced platelet aggregation and related signaling. We show here that the level of collagen-induced tyrosine phosphorylation is significantly reduced by kE and VGVAPG as evidenced by decrease of the tyrosine phosphorylation of a 65-kDa platelet protein that remains to be identified in further studies. Importantly, when tested alone, kE did not induce neither platelet activation nor platelet secretion or exposure of phosphatidylserine, suggesting that kE did not cause desensitization of platelets or affect platelet viability over the time course of the in vitro experiments. The existence of a functional ERC in platelets was further demonstrated by the presence of both Neu-1 and PPCA in human and mouse platelets at the protein level and of EBP, Neu-1, and PPCA in human megakaryocytes at the mRNA level. These 3 subunits form a functional receptor in human platelets that is able to trigger an increase in sialidase activity on binding to EDP. In contrast to PPCA, the catalytic activity of Neu-1 has been shown to be essential for ERC-mediated effects both in vitro 19, 32 and in vivo 13, 14 by catalyzing the local conversion of GM 3 ganglioside into lactosylceramide. 19, 32 Expression of Neu-1 and PPCA has been already reported in platelets. Neu-1 has been shown to be up-regulated at the cell surface after refrigeration and to participate in vWF receptor (GPIbα) desialylation. 33 PPCA has been shown to be secreted on platelet aggregation, 34 but its role in platelet activation remains unknown to date. Unfortunately, because of the unavailability of anti-EBP antibodies, we were unable to demonstrate the presence of EBP at the protein level in platelets. However, the increase in platelet sialidase activity triggered by EDP confirm that EBP is well present at the protein level in platelets.
Deciphering the influence of EDP and the VGVAPG peptide on platelet interaction with collagen under flow conditions led to the unexpected finding that EDP also disrupt immobilization of human and mouse plasma vWF onto collagen fibers as a result of a high affinity of EDP for collagen. Indeed, at 25 μg/mL that represents 0.33 μmol/L (average molecular weight of kE=75 kDa), a strong inhibition of 45% was observed with a maximal effect culminating at 80% to 85% inhibition. In our conditions, both human and mouse plasma vWF were unable to interact with immobilized kE as already reported by Matsui et al 35 and VGVAPG was without effect, suggesting that longer EDP seem to be involved in disruption of plasma vWF immobilization onto collagen.
Specific involvement of EDP in regulating thrombosis and hemostasis was finally confirmed in vivo because kE prolonged mesenteric arteriole occlusion and tail-bleeding time in mice. kE was used at 10 mg/kg, a concentration slightly above the blood EDP concentration measured in wild-type mice (7.7±1.1 mg/kg) and well below the concentrations estimated in high fat diet (14.2±1.1 mg/kg) and diabetic (15.2±1.2 mg/kg) mice. 14 Importantly, injection of the VGVAPG peptide prolonged mesenteric arteriole occlusion and may also increase tail-bleeding time in mice, confirming the specific involvement of the ERC in vivo and most probably of the ERC-mediated effects described here on platelets. This is further strengthened because the VGVAPG peptide has no major effect on vWF binding to collagen.
In conclusion, the current study demonstrates for the first time that EDP originating from elastin fragmentation during vascular aging may be involved in the regulation of thrombosis and hemostasis in vivo. It now remains to clarify the contribution of endogenous EDP in murine models harboring the pathophysiological features of vascular aging because healthy vessels are devoid of atherosclerotic plaques and do not recapitulate all the steps and players involved in the complex process of thrombus formation at sites of atherosclerotic lesions. In addition, these antithrombotic effects of EDP may have deleterious consequences on atherosclerosis progression because intraplaque hemorrhage has been associated with increased risk of plaque rupture. In this study, we further demonstrated that the regulatory role of EDP on thrombosis rely on an original mechanism that involves both EDP-mediated disruption of vWF immobilization onto collagen fibers at the matrix level (receptorindependent) and EDP-mediated effects at the platelet level, leading to decreased aggregation and increase in sialidase activity. Importantly, platelets express a functional ERC that is able to recapitulate the effects observed with kE. However, whether EDP and the VGVAPG peptide are acting by the same mechanism on platelets remains to be elucidated. Indeed, the hypothesis that EDP may also regulate platelet function by a receptor-independent mechanism cannot be totally discarded. Anyway, this study demonstrates for the first time that a functional ERC is present in platelets. On binding to an elastin-derived bioactive GxxPG peptide, such as VGVAPG, the ERC is able to decrease washed platelet aggregation and related signaling and to prolong arteriole occlusion and tail-bleeding time. Because the signaling pathways mediated by the ERC have been shown to transduce signals through the catalytic activity of its Neu-1 subunit, 13, 14, 36 this study opens new avenues in the complexity of the platelet signaling pathways involved during thrombosis and hemostasis and offers the exciting possibility of a potential fine-tuning of platelet receptor sialylation and activation by the ERC. 
